RxDoctor Payments Data

Harrypersad Singh, MD

Internal Medicine · Silsbee, TXNPI 1366427528

Payments from drug & device makers

$1,769in general payments, 2019–2025

Across 116 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$807
  • Pfizer$199
  • GSK$186
  • Inspire Medical Systems, Inc.$130
  • Lilly USA, LLC$89
  • AstraZeneca$82
  • plus $277 from 10 others

What the payments were for

  • Food & beverage$1,769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,769 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$51,254
Medicare patients
235
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$99,852
OzempicSemaglutide79$80,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$65,203
TrulicityDulaglutide58$64,612
JardianceEmpagliflozin33$36,469
MounjaroTirzepatide33$34,581
FarxigaDapagliflozin Propanediol29$27,582
MyrbetriqMirabegron39$27,252
JanuviaSitagliptin Phosphate19$21,809
XareltoRivaroxaban18$9,656
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$9,189
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,043
Breo ElliptaFluticasone/Vilanterol20$7,808
Gabapentin222$4,576
Albuterol Sulfate HfaAlbuterol Sulfate178$4,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$199$99,85288 claims
Lilly USA, LLCTrulicity, Mounjaro$89$99,19391 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$186$82,200117 claims
Novo NordiskOzempic$63$80,85679 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$82$38,19453 claims
MerckJanuvia$12$21,80919 claims
Johnson & JohnsonXarelto$22$9,65618 claims
AbbVieSynthroid$807$3,17040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Silsbee

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →